Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add: Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
A promising new flu vaccine based on mRNA
Nov. 28, 2012
 
According to the latest publication of Nature Biotechnology, an in vitro synthesized, mRNA-based flu vaccine may induce balanced and long-term protective immunity against influenza A virus. This vaccine showed heat-stability and cross-reactivity also.
 
New technology for producing heat-stable vaccines
Dec. 3, 2012
 
A new technology for the production of thermostable vaccines was developed in USA, by utilizing novel formulation and spray-drying processing methods. With this technology, an influenza vaccine product may be stable at 50°C for over 2 months, which may give rise to the extended product shelf life, decreased cost of vaccine stockpiling, and eased deployment of vaccines. It can also help to ensure vaccine potency in remote areas without cold chain.
 
Menactra approved to lower age group in Canada
Dec. 6, 2012
 
Menactra, the Meningococcal polysaccharide diphtheria toxoid conjugate vaccine, has been approved by Health Canada to be used as early as nine months of age. This vaccine prevents meningococcal meningitis and meningococcal diseases caused by Neisseria meningitidis' strains A, C, Y and W135.
 
Gates Foundation awarded $10 million grant for adjuvant research
Dec. 9, 2012
 
A nonprofit biotechnology organization, IDRI, received a nearly $10 million 3-year grant from The Bill & Melinda Gates Foundation to support its work on formulating new and improved adjuvants, predominately focusing on tuberculosis.
 
BravoBio attended Annual Meeting of China Biologicals
Dec. 10, 2012
 
Sponsored by GE Healthcare, BravoBio attended China Biologicals Annual Meeting 2012, held in Hongshan Hotel, Wuhan City, during Dec. 6~7.
 
NIFDC passed the qualification of WHO
Dec. 14, 2012
 
According to SFDA, National Institutes for Food and Drug Control (NIFDC) was enlisted in Qualified Laboratory for Drug Control by World Health Organization (WHO) last month, being No. 26 of this kind worldwide. An inspection group from WHO visited NIFDC early this year and agreed NIFDC met with WHO-GPCL (good practices for pharmaceutical quality control laboratories).
 
FDA approved GSK's quadrivalent seasonal flu vaccine
Dec. 19, 2012
 
FDA approved GSK's new four-strain seasonal flu vaccine Fluarix, which is approved for use in children 3+ and adults. The vaccine can protect against two A virus strains and two B strains and will be available in 2013-2014 flu season.
 
AAP thinks thimerosal in vaccines is safe
Dec. 22, 2012
 
According to Reuters Health, the American Academy of Pediatrics (AAP) stated that the preservative, thimerosal, should not be banned as an ingredient in vaccines. It's cheaper and easier to use multi-dose vials of vaccines, and thimerosal prevents the rest of a multi-dose vial from getting contaminated once a dose is used.
Earlier this year, WHO said replacing thimerosal with an alternative preservative could affect vaccine safety and might cause some vaccines to become unavailable.
 
India will open drug inspection office in China
Dec. 26, 2012
 
India will open its first foreign drug office abroad next year, by sending inspectors to China. Located in Beijing, the office will be in charge of inspecting China manufacturing facilities that export products to India.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next